Clinical Trial

Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors

Study acronym: CMD03
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cells with IL-7Ra signal targeting B7H3 in children with solid tumors patients after complete standard treatments.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-09-23; most recent amendment 2026-02-26.
Status change: Not Yet Recruiting → Recruiting 2025-03-26
Trial Details
NCT Number NCT06612645
Lead Sponsor Chulalongkorn University
Collaborators: King Chulalongkorn Memorial Hospital
Conditions Pediatric Cancers, Solid Tumor Pediatric
Enrollment 9 participants
Start Date 2025-04-01
Primary Completion 2027-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-02